Markets:

Overview

News

Currencies

International

Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

61.26 -0.47 (-0.76%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Analyst Ratings for Cytokinetics ↗

February 17, 2023

Via Benzinga

A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap? ↗

February 17, 2023

The company's biggest moneymakers are soon to lose patent protection.

Via Investor's Business Daily

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

Analyst Ratings for Cytokinetics ↗

December 20, 2022

Via Benzinga

Expert Ratings for Cytokinetics ↗

December 20, 2022

Via Benzinga

What 7 Analyst Ratings Have To Say About Cytokinetics ↗

December 20, 2022

Via Benzinga

Tesla To $175? Here Are 10 Other Price Target Changes For Friday ↗

December 23, 2022

Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022 ↗

December 20, 2022

Via Benzinga

FDA Adcomm Gives Thumbs Down To Cytokinetics' Heart Failure Candidate ↗

December 14, 2022

Via Benzinga

Where Cytokinetics Stands With Analysts ↗

October 11, 2022

Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter:

Via Benzinga

Analyst Ratings for Cytokinetics ↗

July 15, 2022

Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter:

Via Benzinga

Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session ↗

December 14, 2022

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.

Via Benzinga

Cytokinetics AdComm Outcome Might Be Blessing In Disguise, This Analyst Said ↗

December 14, 2022

Via Benzinga

REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday ↗

December 14, 2022

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug ↗

December 14, 2022

The FDA's experts voted 3-8 against the Cytokinetics heart-failure drug.

Via Investor's Business Daily

December 14, 2022

Benzinga

Via Benzinga

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Cytokinetics CEO: Why It's OK Not Being An Overnight Success ↗

October 25, 2022

The company hopes to come out next year with at least one heart-failure drug.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗

October 11, 2022

Upgrades

Via Benzinga

Coca-Cola Price Target Cut By This Analyst? Plus Rocket Pharmaceuticals Likely To Rally Around 306% ↗

October 03, 2022

Wells Fargo cut the price target on The Coca-Cola Company (NYSE: KO) from $72 to $66. Wells Fargo analyst Chris Carey maintained an Overweight rating on the stock. Coca-Cola shares rose 0.3% to $56.20...

Via Benzinga

Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday ↗

September 07, 2022

Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.

Via Benzinga

Swing Trading Stock Watchlist For The Week Of Sept. 6 ↗

September 04, 2022

The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look.

Via Talk Markets

iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday ↗

August 08, 2022

U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

What 5 Analyst Ratings Have To Say About Cytokinetics ↗

August 05, 2022

Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK) within the last quarter:

Via Benzinga

Cytokinetics Records $89M Q2 Sales On Deferred Mavacamten Revenues, Forecasts FY22 Cash Of Over $800M ↗

August 05, 2022

Via Benzinga

Recap: Cytokinetics Q2 Earnings ↗

August 04, 2022

Cytokinetics (NASDAQ:CYTK) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics beat estimated...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 30, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 29, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial ↗

June 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.